Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxxinity Inc VAXX

Healthcare Biotechnology
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the... see more

Recent & Breaking News (PINL:VAXX)

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

GlobeNewswire May 9, 2022

Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference

GlobeNewswire May 5, 2022

Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer's Disease

GlobeNewswire May 2, 2022

Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson's Disease

GlobeNewswire April 28, 2022

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

GlobeNewswire April 6, 2022

Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster

GlobeNewswire March 28, 2022

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

GlobeNewswire March 24, 2022

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

GlobeNewswire March 21, 2022

Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

GlobeNewswire February 11, 2022

Vaxxinity Announces First Parkinson's Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

GlobeNewswire January 12, 2022

Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Support UB-312 Vaccine Study

GlobeNewswire January 10, 2022

Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors

GlobeNewswire January 4, 2022

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

GlobeNewswire December 23, 2021

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 18, 2021

Vaxxinity Announces Pricing of Initial Public Offering

GlobeNewswire November 11, 2021